Escitalopram

Escitalopram is indicated for the treatment of: ; major depressive disorder (MDD) in adults and pediatric patients 12 years of age and older. ; generalized anxiety disorder (GAD) in adults. Additional pediatric use information is approved for AbbVie Inc.’s LEXAPRO (escitalopram) tablets and LEXAPRO (escitalopram) oral solution. However, due to AbbVie Inc.’s marketing exclusivity rights, this drug product is not labeled with that information.

12.1 Mechanism of Action The mechanism of antidepressant action of escitalopram, the S-enantiomer of racemic citalopram, is presumed to be linked to potentiation of serotonergic activity in the central nervous system (CNS) resulting from its inhibition of CNS neuronal reuptake of serotonin (5-HT). Advise the patient to read the FDA-approved patient labeling (Medication Guide).

Pharmacokinetic profiling of Escitalopram demonstrates an elimination half-life of Steady-state plasma equilibrium reached over 9–16 hour t½ intervals for Escitalopram with Approximately 46% to 58% enteral uptake across labeled Escitalopram strengths systemic bioavailability; clearance proceeds via predominantly hepatic biotransformation with renal elimination of polar escitalopram conjugates, reaching clinical onset within maximum serum exposure occurs 2–5 hours after escitalopram dosing.

Titration schedules for Escitalopram (20 mg/1 Tablet, Film Coated → 10 mg/1 Tablet, Film Coated → 5 mg/1 Tablet, Film Coated → 5 mg/5mL Solution → 20 mg/1 Tablet) require excluding escitalopram tablets are contraindicated in patients:; taking maois with escitalopram tablets or within 14 days of stopping treatment with escitalopram tablets because of an increased risk of serotonin syndrome.; the use of escitalopram tablets within 14 days of stopping an maoi intended to treat psychiatric disorders is also contraindicated .; real-world patient logs highlight nausea (12.3% of reports), headache (7.2% of reports), insomnia (6.6% of reports) alongside a 89.00% Worth-It consensus.